Pharming Group Reports Strong FY25 Financial Turnaround and Positive 2026 Revenue Guidance

summarizeSummary

Pharming Group reported a strong financial performance for full year 2025, achieving profitability and positive cash flow, and issued positive revenue guidance for 2026, despite receiving an FDA Complete Response Letter for its pediatric Joenja® sNDA.

check_boxKey Events

• Strong FY2025 Financial Performance

  Full year 2025 total revenues increased by 27% to US$376.1 million, driven by RUCONEST® and Joenja® growth. The company achieved an operating profit of US$25.8 million (compared to a loss in 2024) and US$54.7 million in net cash flow from operations (compared to negative in 2024).

• Positive 2026 Revenue Guidance

  Pharming anticipates 2026 total revenues between US$405.0 million and US$425.0 million, representing 8% to 13% growth, primarily driven by accelerating growth for Joenja® and continued growth for RUCONEST®.

• Joenja® Pediatric sNDA Receives FDA Complete Response Letter

  On January 30, 2026, the FDA issued a CRL for the supplemental New Drug Application (sNDA) for Joenja® (leniolisib) for children aged 4 to 11 years, requesting additional pediatric pharmacokinetic data and clarification on an analytical batch testing method. The company plans a Type A meeting with the FDA to discuss the path forward.

• Advancing Pipeline and Regulatory Milestones

  The company is advancing its clinical pipeline with Phase II leniolisib readouts in PIDs with immune dysregulation expected in H2 2026, and pivotal FALCON study enrollment completion for napazimone (KL1333) in primary mitochondrial disease in 2026. Regulatory decisions for Joenja® in EEA and Japan are expected in H1 2026 and by end of March 2026, respectively.

auto_awesomeAnalysis

Pharming Group N.V. has reported a significant financial turnaround for the full year 2025, moving from an operating loss to a profit and achieving positive cash flow from operations. This strong performance was driven by robust revenue growth from both RUCONEST® and Joenja®, with the company outperforming its prior revenue guidance. The positive momentum is expected to continue into 2026, with revenue guidance projecting 8% to 13% growth. While the company received a Complete Response Letter (CRL) from the FDA for its pediatric Joenja® sNDA, indicating a delay in market expansion for this age group, management has a clear plan to address the FDA's feedback. The overall financial health and positive outlook for 2026, coupled with ongoing pipeline advancements and other regulatory progress for Joenja®, present a strong operational picture for investors.